Literature DB >> 19834783

Thrombolytic efficacy of recombinant human microplasmin in a canine model of copper coil-induced coronary artery thrombosis.

Christophe Dommke1, Oliver Turschner, Jean-Marie Stassen, Frans Van de Werf, H Roger Lijnen, Peter Verhamme.   

Abstract

We investigated the in vitro fibrinolytic properties of microplasmin, the isolated proteinase domain of plasmin, and its thrombolytic efficacy in a coronary artery thrombosis model in dogs. The amidolytic and fibrinolytic activity of recombinant microplasmin was compared with natural human plasmin. The thrombolytic efficacy of microplasmin was studied in a canine model of copper coil induced coronary artery thrombosis. Animals were randomly assigned to one of six treatment regimens, each with five animals per cohort. Four treatment groups received an intravenous bolus of microplasmin followed by an intravenous infusion of microplasmin for 1 h (1 mg/kg + 1.5 mg/kg/h with or without abciximab or 2 mg/kg + 3 mg/kg/h). In two treatment groups, microplasmin was administered intracoronary. Bolus administration was followed by a 1-h infusion if coronary flow was incompletely restored after the initial bolus administration (1 mg/kg + 1.5 mg/kg/h or 2 mg/kg + 3 mg/kg/h, respectively). The thrombolytic efficacy was documented by repeated angiographies and the coronary perfusion was assessed with the Thrombolysis in Myocardial Infarction (TIMI) grading. No significant differences between plasmin and microplasmin were observed with respect to the catalytic efficiencies towards the synthetic chromogenic substrates S-2403 or S-2444. The concentration required for 50% lysis of purified fibrin clots in 3 h, was approximately 100 nM for microplasmin compared to 20 nM for natural plasmin. Intravenous bolus administration of microplasmin restored TIMI 3 coronary flow in 0/5, 0/5, 1/5 and 2/5, respectively, whereas intracoronary bolus administration restored TIMI 3 coronary flow in 1/5 and 4/5 (1 mg/kg and 2 mg/kg, respectively) (ANOVA P < 0.05). TIMI 3 coronary flow was obtained in 0/5, 2/5, 2/5 and 3/5, respectively, during subsequent intravenous administration and in 5/5 and 4/5 in case of intracoronary administration (ANOVA P < 0.05). When compared to natural plasmin, the catalytic efficiency of microplasmin towards chromogenic substrates was similar, but the fibrinolytic potency of microplasmin towards fibrin clots was lower. Intracoronay administration of microplasmin effectively lysed coronary thrombosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19834783     DOI: 10.1007/s11239-009-0400-9

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  20 in total

1.  Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit.

Authors:  V J Marder; K Landskroner; V Novokhatny; T P Zimmerman; M Kong; J J Kanouse; G Jesmok
Journal:  Thromb Haemost       Date:  2001-09       Impact factor: 5.249

Review 2.  Alfimeprase: a novel recombinant direct-acting fibrinolytic.

Authors:  Steven R Deitcher; Walter D Funk; James Buchanan; Shouchun Liu; Michael D Levy; Christopher F Toombs
Journal:  Expert Opin Biol Ther       Date:  2006-12       Impact factor: 4.388

3.  Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis.

Authors:  F Van de Werf; I K Jang; D Collen
Journal:  J Cardiovasc Pharmacol       Date:  1987-01       Impact factor: 3.105

4.  Comparison of a synthetic antithrombin III-binding pentasaccharide and standard heparin as an adjunct to coronary thrombolysis.

Authors:  S V Pislaru; C Pislaru; X Zhu; J Arnout; T Stassen; P Vanhove; J M Herbert; D G Meuleman; F Van de Werf
Journal:  Thromb Haemost       Date:  1998-06       Impact factor: 5.249

5.  Synergistic fibrinolysis: combined effects of plasminogen activators and an antibody that inhibits alpha 2-antiplasmin.

Authors:  G L Reed; G R Matsueda; E Haber
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

6.  Clot-selective coronary thrombolysis with tissue-type plasminogen activator.

Authors:  S R Bergmann; K A Fox; M M Ter-Pogossian; B E Sobel; D Collen
Journal:  Science       Date:  1983-06-10       Impact factor: 47.728

7.  On the specific interaction between the lysine-binding sites in plasmin and complementary sites in alpha2-antiplasmin and in fibrinogen.

Authors:  B Wiman; H R Lijnen; D Collen
Journal:  Biochim Biophys Acta       Date:  1979-07-25

8.  Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology.

Authors:  F Van de Werf; S R Bergmann; K A Fox; H de Geest; C F Hoyng; B E Sobel; D Collen
Journal:  Circulation       Date:  1984-03       Impact factor: 29.690

9.  Coronary thrombolysis in dogs with intravenously administered human pro-urokinase.

Authors:  D Collen; D Stump; F van de Werf; I K Jang; M Nobuhara; H R Lijnen
Journal:  Circulation       Date:  1985-08       Impact factor: 29.690

Review 10.  Pre-clinical studies of plasmin: superior benefit-to-risk ratio of plasmin compared to tissue plasminogen activator.

Authors:  Victor J Marder
Journal:  Thromb Res       Date:  2008-08-22       Impact factor: 3.944

View more
  1 in total

1.  2022 Update of the Consensus on the Rational Use of Antithrombotics and Thrombolytics in Veterinary Critical Care (CURATIVE) Domain 6: Defining rational use of thrombolytics.

Authors:  Claire R Sharp; Marie-Claude Blais; Corrin J Boyd; Benjamin M Brainard; Daniel L Chan; Armelle de Laforcade; Robert Goggs; Julien Guillaumin; Alex Lynch; Erin Mays; Duana McBride; Tommaso Rosati; Elizabeth A Rozanski
Journal:  J Vet Emerg Crit Care (San Antonio)       Date:  2022-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.